Breast cancer pseudometastasis in a sentinel lymph node with cytokeratin-positive debris

Breast Journal

Volumn 11, Issue 2, 2005, Pages 134-137

  Rao, Rohini S ^a   Taylor, James ^b   Palmer, James ^b   Jennings, William C ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Regional Medical Laboratory   (United States)

Author keywords

Breast cancer; Breast neoplasms; Cytokeratin; Immunohistochemistry; Lymph nodes; Pseudometastasis; Sentinel lymph node biopsy

Indexed keywords

BIOLOGICAL MARKER; CD68 ANTIGEN; CYTOKERATIN; EPITHELIAL MEMBRANE ANTIGEN;

AGED; ARTICLE; BREAST CANCER; CANCER INFILTRATION; CASE REPORT; CELL STRUCTURE; FEMALE; FROZEN SECTION; HISTIOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MACROPHAGE; MASTECTOMY; PHAGOCYTOSIS; PSEUDOMETASTASIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODES; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 15444372242     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2005.21680.x     Document Type: Article

References (20)

1. Treatment of early-stage breast cancer, National Institutes of Health Consensus Development Conference statement, June 18-21, 1990. NIH Consens Statement 1990;8:1-19.
2. Jennings WC. Why perform randomized clinical trials for sentinel node surgery for breast cancer [letter]? Am J Surg 2003;185:601-2.
3. Kern KA. Breast lymphatic mapping using subareolar injections of blue dye and radiocolloid: Illustrated technique. J Am Coll Surg 2001;192:545-50.
4. Klimberg VS, Rubio IT, Henry R, et al. Subareolar versus peritumoral injection for location of sentinel lymph node. Ann Surg 1999;229:860-65.
5. Clare SE, Sener SF, Wilkens W, et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997;4:447-51.
6. Ludwig Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-68.
7. Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol 1997;66:7-10.
8. Thor A. A revised staging system for breast cancer. Breast J 2004;10:S15-18.
9. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-41.
10. Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of high-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001;136:688-92.
11. Tanis PJ, Boom RPA, Schraffordt Koops H, et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 2001;8:222-26.
12. Viale G, Silvano B, Giovanni M, et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999;85:2433-38.
13. Rubio IT, Korourian S, Cowan C, et al. Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Ann Surg Oncol 1998;5:689-94.
14. Association of Directors of Anatomic and Surgical Pathology. Recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Am J Clin Pathol 2001;115:799-801.
15. Page DL, Carter BA. Sentinel lymph nodes, breast cancer, and pseudometastases. Breast Dis 2002;12:362-63.
16. Fisher CJ, Hill S, Millis RR. Benign lymph node inclusions mimicking metastatic carcinoma. J Clin Pathol 1994;47:245-47.
17. Stitzenberg KB, Calvo BF, Iacocca MV, et al. Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer. Am J Clin Pathol 2002;117:729-37.
18. Jakub JW, Diaz NM, Ebert MD, et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg 2002;184:302-6.
19. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer, 2002.
20. Xu X, Roberts SA, Pasha TL, Zhang PJ. Undesirable cytokeratin immunoreactivity of native nonepithelial cells in sentinel lymph nodes from patients with breast carcinoma. Arch Pathol Lab Med 2000;124:1310-13.